All In Biotech

Drug Trial Radar · NCT05534984

Study of Tecovirimat for Human Mpox Virus

A Randomized, Placebo-Controlled, Double-Blinded Trial of the Safety and Efficacy of Tecovirimat for the Treatment of Human Mpox Virus Disease

Last checked: Nov 19, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 719 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

719

Actual

Start

Sep 8, 2022

Primary completion

Oct 23, 2024

Study completion Feb 22, 2025

Sponsor

Sponsor type
NIH
Collaborators
SIGA Technologies
First posted
Sep 10, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to see if tecovirimat is safe and successful at treating mpox. The main questions were whether tecovirimat reduced time to lesion resolution and pain compared to placebo (no treatment).

Conditions

  • MPOX

Interventions

  • Tecovirimat Oral CapsuleDrug

    * Participants weighing 25 kg to less than 40 kg - Tecovirimat 400 mg every 12 hours for 14 days * Participants weighing 40 kg to less than 120 kg - Tecovirimat 600 mg every 12 hours for 14 days * Participants weighing 120 kg and over - Tecovirimat 600 mg every 8 hours for 14 days

  • Placebo for TecovirimatDrug

    * Participants weighing 25 kg to less than 40 kg - Placebo for Tecovirimat 400 mg every 12 hours for 14 days * Participants weighing 40 kg to less than 120 kg - Placebo for Tecovirimat 600 mg every 12 hours for 14 days * Participants weighing 120 kg and over - Placebo for Tecovirimat 600 mg every 8 hours for 14 days

  • Tecovirimat Oral Capsule (Open Label)Drug

    * Participants weighing \<3 kg - Tecovirimat 33.3 mg every 12 hours for 14 days * Participants weighing 3 kg to less than 6 kg- Tecovirimat 50 mg every 12 hours for 14 days * Participants weighing 6 kg to less than 13 kg - Tecovirimat 100 mg every 12 hours for 14 days * Participants weighing 13 kg to less than 25 kg - Tecovirimat 200 mg every 12 hours for 14 days * Participants weighing 25 kg to less than 40 kg - Tecovirimat 400 mg every 12 hours for 14 days * Participants weighing 40 kg to less than 120 kg - Tecovirimat 600 mg every 12 hours for 14 days * Participants weighing 120 kg and over - Tecovirimat 600 mg every 8 hours for 14 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cumulative Proportion With Clinical Resolution by Day 29Time frame: From study entry through 28 days of follow-up (i.e., Day 29)

Locations

54 sites in 6 countries. Site status is shown where the registry gives one.

  • Alabama CRS

    Birmingham, Alabama

  • Kaiser Permanente Los Angeles Medical Center

    Los Angeles, California

  • Los Angeles LGBT Center CRS

    Los Angeles, California

  • UCLA CARE Center CRS

    Los Angeles, California

  • University of California, Davis CRS

    Sacramento, California

  • UCSD Antiviral Research Center CRS

    San Diego, California

  • University of California, San Francisco HIV/AIDS CRS

    San Francisco, California

  • Harbor University of California Los Angeles Center

    Torrance, California

  • University of Colorado Denver NICHD CRS

    Aurora, Colorado

  • University of Colorado Hospital CRS

    Aurora, Colorado

  • Denver Public Health CRS

    Denver, Colorado

  • University of Florida

    Gainesville, Florida

  • University of Florida Jacksonville NICHD CRS

    Jacksonville, Florida

  • University of Miami / Jackson Memorial Hospital

    Miami, Florida

  • Univ. of South Florida (USF) College of Medicine A

    Tampa, Florida

  • The Ponce de Leon Center CRS

    Atlanta, Georgia

  • Rush University Cook County Hospital Chicago NICHD CRS

    Chicago, Illinois

  • Johns Hopkins University CRS

    Baltimore, Maryland

  • Massachusetts General Hospital CRS (MGH CRS)

    Boston, Massachusetts

  • Brigham and Women's Hospital Therapeutics

    Boston, Massachusetts

  • Henry Ford Hospital CRS

    Detroit, Michigan

  • Washington University Therapeutics (WT) CRS

    St Louis, Missouri

  • New Jersey Medical School Clinical Research Center

    Newark, New Jersey

  • Weill Cornell Chelsea CRS

    New York, New York

  • Mount Sinai West Samuels CRS

    New York, New York

  • Harlem Prevention Center

    New York, New York

  • Columbia Physicians & Surgeons (P&S) CRS

    New York, New York

  • Weill Cornell Uptown CRS

    New York, New York

  • Bronx-Lebanon Hospital Center NICHD CRS

    New York, New York

  • Infectious Disease Clinical and Translational Research

    New York, New York

  • University of Rochester Adult HIV Therapeutic

    Rochester, New York

  • SUNY Stony Brook NICHD CRS

    Stony Brook, New York

  • Duke University Medical Center CRS

    Durham, North Carolina

  • Wake Forest Baptist Medical Center CRS

    Winston-Salem, North Carolina

  • Cincinnati CRS

    Cincinnati, Ohio

  • Case Western Reserve University CTU

    Cleveland, Ohio

  • Ohio State University CRS

    Columbus, Ohio

  • Penn Therapeutics CRS

    Philadelphia, Pennsylvania

  • University of Pittsburgh CRS

    Pittsburgh, Pennsylvania

  • St. Jude Children's Research Hospital ATN CRS

    Memphis, Tennessee

Showing 40 of 54 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.